Clinical trial
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low…
NCT00338494 · Yale University, Other · Completed
Key facts
| NCT number | NCT00338494 |
|---|---|
| Title | Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma |
| Official title | Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermed.Grade B-Cell/T-Cell Lymphoma |
| Lead sponsor | Yale University, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | B-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Clofarabine |
| Enrollment | 16 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2010 |
| Completion | Apr 1, 2011 |
| First posted | Jun 20, 2006 |
| Last update posted | Jan 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: